HER2+ Breast Cancer Pilot Study

Blood was drawn from 16 breast cancer patients and enriched for Circulating Tumor Cells (CTCs) using LiquidScan. Isolated cells were analyzed for HER2 positivity using FISH. Of 11 patients that tested HER2- after needle biopsy, LiquidScan revealed 2 of these to be HER2+. Except for these two patients that needle biopsy missed, LiquidScan mirrored exactly the needle biopsy results.

These results while being extended in a larger study, indicate that cell-based liquid biopsy, made possible by LiquidScan, as an accurate less invasive method for monitoring breast cancer in patients, could lead to more frequent monitoring and better healthcare.